Virax Biolabs may sell up to $2,070,060.20 of ordinary shares through Wainwright under its updated at-the-market program. Investors can compare that available capacity with approximately $3,658,152 of prior sales under the same agreement, while the supplement also details the public-float calculation supporting the limit.

Key Highlights

  • The prior ordinary shares sold under the Original and Second Prospectus Supplements had an aggregate sales price of approximately $3,658,152.
  • The public float was calculated at $8,421,181 using 1,324,085 ordinary shares held by non-affiliates.
  • Virax Biolabs ordinary shares closed at $2.56 on Sep. 3.

Virax Biolabs Group Limited (NASDAQ: VRAX) may sell up to $2,070,060.20 of ordinary shares through H.C. Wainwright & Co. under an updated at-the-market arrangement.

$2.07M Ordinary-Share Capacity

The ordinary shares carry a Par Value of $0.025 per share. The arrangement with Wainwright is dated Jan. 22, 2024, and the updated prospectus supplement is dated Sep. 4, 2026. Virax Biolabs said the new amount reflects the maximum offering price permitted under the applicable registration limitation and its public float. The supplement states that further ordinary-share sales would require another prospectus supplement if additional capacity becomes available.

Public Float Calculation

Virax Biolabs’ public float was calculated at $8,421,181 using 1,324,085 ordinary shares held by non-affiliates and a $6.36 per-share price. The ordinary shares closed at $2.56 on Sep. 3, 2026.